KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Return on Invested Capital (2021 - 2025)

Rigel Pharmaceuticals has reported Return on Invested Capital over the past 4 years, most recently at 1.33% for Q4 2025.

  • Quarterly results put Return on Invested Capital at 1.33% for Q4 2025, up 1263.0% from a year ago — trailing twelve months through Dec 2025 was 1.33% (up 1263.0% YoY), and the annual figure for FY2025 was 1.75%, up 599.0%.
  • Return on Invested Capital for Q4 2025 was 1.33% at Rigel Pharmaceuticals, up from 0.94% in the prior quarter.
  • Over the last five years, Return on Invested Capital for RIGL hit a ceiling of 6.72% in Q3 2022 and a floor of 51.44% in Q2 2022.
  • Median Return on Invested Capital over the past 4 years was 0.12% (2021), compared with a mean of 4.61%.
  • Biggest five-year swings in Return on Invested Capital: plummeted -5138bps in 2022 and later surged 1263bps in 2025.
  • Rigel Pharmaceuticals' Return on Invested Capital stood at 0.32% in 2021, then soared by 2179bps to 6.72% in 2022, then tumbled by -268bps to 11.3% in 2024, then skyrocketed by 112bps to 1.33% in 2025.
  • The last three reported values for Return on Invested Capital were 1.33% (Q4 2025), 0.94% (Q3 2025), and 1.5% (Q2 2025) per Business Quant data.